UnitedHealth Group is one of the largest private health insurers and provides medical benefits to about 51 million members globally, including 1 million outside the US as of December 2025. As a leader in employer-sponsored, self-directed, and government-backed insurance plans, UnitedHealth has obtained massive scale in medical insurance. Along with its insurance assets, UnitedHealth's Optum franchises help create a healthcare services colossus that spans everything from pharmaceutical benefits to providing outpatient care and analytics to affiliates and third parties.
Last trade$392.57
Day change-$19.45 (-4.72%)
Day range$389.18 – $409.84
Volume4,598,974
Market cap$369.18B
OpenXNYS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$369.18B
Price / earnings
26.14×
Price / book
3.75×
Price / sales
0.82×
EV / sales
0.92×
EV / EBITDA
16.67×
Profitability
Earnings per share
$15.76
Return on assets
4.56%
Return on equity
14.34%
Dividend yield
2.19%
Liquidity and leverage
Debt / equity
0.74×
Current ratio
1.88×
Quick ratio
1.88×
Cash ratio
0.72×
Cash flow
Price / cash flow
13.66×
Price / free cash flow
15.63×
Free cash flow
$23.62B
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for UNH, quarterly periods
Line item
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Q3 FY2024 Sep 30, 2024
Revenue
$112.03B
$110.59B
$113.22B
$113.16B
$111.62B
$108.54B
$100.81B
$100.82B
Cost of revenue
$75.36B
$73.49B
$82.04B
$79.96B
$78.59B
$73.41B
$67.04B
$65.96B
Gross profit
$36.67B
$37.1B
$31.17B
$33.2B
$33.03B
$35.13B
$33.77B
$34.86B
Selling, general and administrative
$14.27B
$15.39B
$18.11B
$16.32B
$13.78B
$13.59B
$13.54B
$14.32B
Research and development
—
—
—
—
—
—
—
—
Total operating expenses
$104.04B
$102.73B
$112.84B
$108.85B
$106.47B
$100.46B
$93.03B
$92.11B
Operating income
$7.99B
$7.86B
$380M
$4.32B
$5.15B
$8.09B
$7.77B
$8.71B
Interest expense
-$962M
-$955M
-$974M
-$1B
-$1.03B
-$998M
-$1B
-$1.07B
Income before taxes
$6.97B
$7.96B
-$720M
$3.23B
$4.08B
$8.11B
$6.79B
$7.61B
Income taxes
$1.3B
$1.48B
-$938M
$686M
$510M
$1.63B
$1.01B
$1.36B
Net income
$5.67B
$6.48B
$218M
$2.54B
$3.57B
$6.47B
$5.78B
$6.26B
Net income attributable to common shareholders
$5.48B
$6.28B
$10M
$2.35B
$3.41B
$6.29B
$5.54B
$6.06B
EBITDA
$9.03B
$8.89B
$1.5B
$5.41B
$6.23B
$9.15B
$8.81B
$9.75B
Basic earnings per share
$6.06
$6.92
$0.01
$2.59
$3.76
$6.90
$6.04
$6.56
Diluted earnings per share
$6.04
$6.90
$0.01
$2.59
$3.74
$6.85
$5.92
$6.51
Recent news
Company coverage with links to the original publishers.
UnitedHealth Group (UNH) has gained 24.8% year-to-date, outperforming the broader Medical sector's 9% average gain. The company holds a Zacks Rank #2 (Buy) with improved analyst sentiment, as consensus earnings estimates have risen 4.6% in the past quarter. However, UNH slightly underperforms its Medical-HMOs industry group, which has averaged 28.6% gains. Alto Neuroscience (ANRO) is also highlighted as an outperformer with 52.4% year-to-date returns.
UnitedHealth Group's Optum Rx segment increased operating earnings by 10.9% to $1.72 billion in Q3 2026 despite a 5.1% decline in adjusted prescriptions, driven by biosimilar adoption and operational efficiencies. However, membership losses and declining prescription volumes pose sustainability challenges for future growth. Specialty pharmacy volumes grew 2.6%, offering some offset to overall volume pressures.
UnitedHealth Group (UNH) reported Q3 2026 adjusted EPS of $4.69, beating consensus estimates of $4.12, with a 60.6% year-over-year increase. The company raised its 2026 adjusted EPS guidance to at least $20.5 from the previous range of $19.5-$20, driven by improved medical cost management and strong performance from Optum Insight and Optum Rx. Despite a slight revenue decline of 0.4% year-over-year to $112.7 billion, the company improved its medical care ratio to 88.4% and generated strong operating cash flows of $25.1 billion in the first nine months of 2026.
UnitedHealth Group has demonstrated strong management performance in correcting 2025 miscalculations, with earnings jumping 60% and guidance raised for the third time in the year. The article examines whether the stock remains a good investment opportunity despite its recent strong performance.
CVS Health announced plans to separate into two independent publicly traded companies by mid-2028: one retaining Aetna, Caremark, and care operations, and another housing retail pharmacies and MinuteClinic. The split aims to improve capital allocation and operating flexibility, though it carries execution risks, restructuring costs, and potential dis-synergies during the transition period.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
Declared upcoming dividend$2.32 per share
Declared
Nov 3, 2026
Ex-dividend
Dec 7, 2026
Pay date
Dec 15, 2026
Ex-dividend
Amount / share
Pay date
Type
Sep 14, 2026
$2.32
Sep 22, 2026
recurring
Jun 15, 2026
$2.32
Jun 23, 2026
recurring
Mar 9, 2026
$2.21
Mar 17, 2026
recurring
Dec 8, 2025
$2.21
Dec 16, 2025
recurring
Sep 15, 2025
$2.21
Sep 23, 2025
recurring
Stock splits
Historical share-structure events and their execution dates.